Literature DB >> 8137715

Incidence of altered glucose tolerance in liver cirrhosis.

S Gentile1, C Loguercio, R Marmo, L Carbone, C Del Vecchio Blanco.   

Abstract

Even though the association between liver cirrhosis and glucose tolerance alterations has been well documented, no data are available on the incidence of this association. In this paper we firstly report the results of a 4-year prospective longitudinal study performed on well-compensated cirrhotic patients with a normal glucose tolerance, in order to evaluate the incidence of glucose tolerance alterations with respect to liver efficiency during the time. The incidence of a diabetic response to a standard OGTT was 4.4% after a 1-year and 21.2% after a 4-year follow-up in stable cirrhotics. These figures are significantly higher than in the general population of our country. This large incidence was even significantly higher in cirrhotics with worsening liver efficiency at the end of the study (35.3%, P < 0.0001). Sex, family history of diabetes, alcoholic aetiology of the cirrhosis, and increment of portal hypertension do not seem to have any significant influence on the frequency of altered glucose tolerance. Therefore, we propose that liver cirrhosis and its worsening play a primary role as diabetogenic risk factors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8137715     DOI: 10.1016/0168-8227(93)90130-w

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  10 in total

1.  Relationship of hepatitis C virus infection with diabetes in the U.S. population.

Authors:  Constance E Ruhl; Andy Menke; Catherine C Cowie; James E Everhart
Journal:  Hepatology       Date:  2014-08-25       Impact factor: 17.425

2.  The investigation of glucose metabolism and insulin secretion in subjects of chronic hepatitis B with cirrhosis.

Authors:  Chun-Hui Guo; Ting-Ting Sun; Xi-Ding Weng; Jian-Chun Zhang; Jian-Xin Chen; Guo-Jiong Deng
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.

Authors:  Y Kihara; Y Ogami; A Tabaru; H Unoki; M Otsuki
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

4.  Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease.

Authors:  Ju Dong Yang; Fowsiyo Ahmed; Kristin C Mara; Benyam D Addissie; Alina M Allen; Gregory J Gores; Lewis R Roberts
Journal:  Hepatology       Date:  2019-10-21       Impact factor: 17.425

Review 5.  Why does NAFLD predict type 2 diabetes?

Authors:  Guido Lattuada; Francesca Ragogna; Gianluca Perseghin
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

6.  Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.

Authors:  Ju Dong Yang; Hager Amed Mohamed; Jessica L Cvinar; Gregory J Gores; Lewis R Roberts; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2016-08-16       Impact factor: 10.864

Review 7.  Viewpoints on the way to a consensus session: where does insulin resistance start? The liver.

Authors:  Gianluca Perseghin
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

Review 8.  Hepatogenous diabetes: Knowledge, evidence, and skepticism.

Authors:  Ramesh Kumar; Diego García-Compeán; Tanmoy Maji
Journal:  World J Hepatol       Date:  2022-07-27

9.  Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease.

Authors:  Shoko Kuriyama; Yoshiyuki Miwa; Hideki Fukushima; Hironori Nakamura; Katsuhisa Toda; Makoto Shiraki; Masahito Nagaki; Mayumi Yamamoto; Eiichi Tomita; Hisataka Moriwaki
Journal:  J Clin Biochem Nutr       Date:  2007-03       Impact factor: 3.114

Review 10.  Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease.

Authors:  Angelo Armandi; Chiara Rosso; Gian Paolo Caviglia; Elisabetta Bugianesi
Journal:  Metabolites       Date:  2021-03-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.